Dual Antiplatelet Therapy in NSTEMI: Successfully Navigating the DAPT Dilemma.

Abstract

Non-ST Segment Elevation Myocardial Infarction (NSTEMI) is a leading cause of morbidity and mortality worldwide despite advances in therapy, necessitating a careful balance between preventing ischemic events and minimizing bleeding risks. Dual Antiplatelet Therapy (DAPT) plays a critical role in reducing recurrent myocardial infarction (MI), stent thrombosis, and cardiovascular death. However, its benefits in preventing thrombotic events come with an increased risk of major bleeding complications. Precision medicine, using patient-specific data and risk stratification tools, allows for the clinicians to better tailor treatment to optimize efficacy while minimizing adverse outcomes. This approach ensures the most appropriate care for each patient, improving outcomes in NSTEMI management.